Benzinga | Sep 22, 2020 08:37AM EDT

AcelRx Awarded $3.6M US Army Contract For DSUVIA

REDWOOD CITY, Calif., Sept. 22, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the U.S. Army has awarded AcelRx with an initial contract of up to approximately $3.6 million for the purchase of DSUVIA to support a study to aid the development of clinical practice guidelines. Orders under the contract may be fulfilled over the next four years as specified in the agreement, with an initial purchase expected this year.